Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 4 25 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 4 25 IN DEXTROSE 5 IN PLASTIC CONTAINER.
EPANOVA vs TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Travasol 4.25% in dextrose 5% is a parenteral nutrition solution providing amino acids and carbohydrates. Amino acids serve as substrates for protein synthesis and other metabolic processes, while dextrose provides a source of glucose for energy. The combination supports tissue repair, growth, and maintenance.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion: 500-2000 mL per day as a source of amino acids and calories, adjusted based on metabolic needs and clinical response. Typical adult dose is 1.5-2.0 g/kg/day of amino acids (equivalent to 35-47 mL/kg/day of TRAVASOL 4.25% IN DEXTROSE 5%) administered via central or peripheral line.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Not applicable as a combined product; amino acids have half-lives of minutes to hours depending on individual amino acid, and dextrose has a half-life of ~15-20 minutes under normal glucose homeostasis.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Travasol 4.25% in dextrose 5% is a parenteral nutrition solution; the amino acids are metabolized and the nitrogen is excreted primarily in urine as urea (≥90%). Dextrose is metabolized to CO2 and water, with minimal biliary or fecal excretion.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution